The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of first-line combined chemotherapy bevacizumab with modified RPMI regimen for elderly or frail patients with unresectable or metastatic colorectal cancer (OGSG0802) update analysis.
Taroh Satoh
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma; Yakult Honsha
Takeshi Kato
Honoraria - Chugai Pharma
Motoki Yoshida
No relevant relationships to disclose
Yasuhiro Miyake
No relevant relationships to disclose
Shigeyoshi Iwamoto
No relevant relationships to disclose
Masato Nakamura
No relevant relationships to disclose
Daisuke Sakai
Research Funding - Chugai Pharma; Yakult Honsha
Masaki Matsuoka
No relevant relationships to disclose
Toshio Otsuji
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose